New drug applications approved by US FDA as of 16 - 30 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Both the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) are reliable methods of determining disease activity in Singaporeans with axial spondyloarthritis (axSpA), according to a recent study.
The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.
In cancer patients with rheumatoid arthritis (RA) treated with immune checkpoint inhibitors (ICIs), rates of immune-related adverse events (irAEs) are similar to those reported in patients without autoimmune diseases, with most symptoms being manageable.
New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The osteoporosis medications teriparatide, romosozumab, raloxifene and denosumab all confer significant benefits for reducing vertebral and hip fractures and inducing changes in bone mineral density at the femoral neck as compared with placebo, according to the results of a network meta-analysis.
In patients with active psoriatic arthritis (PsA), treatment with secukinumab at 300 and 150 mg with or without loading regimen inhibits radiographic progression, the rates of which remaining low over 52 weeks of treatment, while showing consistent clinical efficacy and a favourable safety profile, according to the 52-week data from phase III FUTURE 5 trial.
The Janus kinase inhibitor tofacitinib remained effective and safe even after discontinuing the csDMARD* methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) who achieved low disease activity (LDA) with a combination of the two drugs, the ORAL Shift** trial suggests, highlighting the feasibility of methotrexate withdrawal in this setting.
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.